BioWorld

Feb. 27, 2003

View Archived Issues

FDA Approves Guilford's Gliadel As First-Line Therapy For Glioma

The FDA issued Guilford Pharmaceuticals Inc. approval to expand the use of the Gliadel Wafer as a first-line therapy for patients with high-grade malignant glioma. (BioWorld Today) Read More

Buyouts Making As Much Sense As Collaborations In Some Cases

Read More

Helicobacter pylori Bacteria Holed Up In The Stomach Is Often A Life Sentence Of Gut Damage, Cancer

Read More

Affinium Purchases Preclinical Antibiotic Compounds From GSK

Read More

Hollis-Eden Garners $10 Million With Sale Of Convertible Notes

Read More

Celltech Joins Bidding War For OGS; Offer Called Inadequate'

Read More

Amgen Business Overview Through 2005 Well Received

Read More

Other News To Note

Read More